Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Opus Genetics's share price for the quarter that ended in Mar. 2025 was $0.9818. Opus Genetics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2025 was 45.48 Mil. Therefore, Opus Genetics's market cap for the quarter that ended in Mar. 2025 was $44.66 Mil.
Opus Genetics's quarterly market cap
increased
from Sep. 2024 ($34.32 Mil) to Dec. 2024 ($37.57 Mil) and
increased
from Dec. 2024 ($37.57 Mil) to Mar. 2025 ($44.66 Mil).
Opus Genetics's annual market cap
declined
from Dec. 2022 ($73.64 Mil) to Dec. 2023 ($72.17 Mil) and
declined
from Dec. 2023 ($72.17 Mil) to Dec. 2024 ($37.57 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Opus Genetics's Enterprise Value for Today is $18.59 Mil.
Opus Genetics Market Cap Historical Data
The historical data trend for Opus Genetics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Opus Genetics's Market Cap
For the Biotechnology subindustry, Opus Genetics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's Market Cap distribution charts can be found below:
* The bar in red indicates where Opus Genetics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Opus Genetics's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (NAS:IRD) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Opus Genetics Market Cap Related Terms
Thank you for viewing the detailed overview of Opus Genetics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IRD has been successfully added to your 